Tests IOV-3001 with lifileucel in adults with advanced melanoma
Tests IOV-3001, a modified interleukin-2 treatment, in adults with advanced melanoma.
Key facts
- Who runs it
- Iovance Biotherapeutics, Inc.
- Where
- Chapel Hill, Denver, and Nashville, United StatesSee the 3 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 42 people, planned
- Started
- 11 Mar 2025
- Expected to end
- Jul 2032
- Type of study
- Interventional
- Treatments tested
- IOV-3001
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that cannot be removed by surgery or has spread, and who will receive lifileucel after earlier treatment.
- Age
- 18 to 70 years.
- Sex
- All sexes can join.
- Disease stage
- Melanoma that cannot be removed by surgery or has spread. The disease has progressed on a PD-1/PD-L1 blocking antibody, or within 12 weeks after the last dose. Uveal (eye) melanoma is allowed only in Phase 1, Part 1.
- Earlier treatment
- Must have had a PD-1/PD-L1 blocking antibody. If the tumor is BRAF V600 mutation positive, must have received or refused a BRAF inhibitor with or without a MEK inhibitor. Uveal melanoma: tebentafusp received or refused, if available as standard of care. Must have recovered from side effects of earlier cancer treatment.
- Biomarker or test result
- BRAF V600 mutation status matters for earlier treatment. For uveal melanoma, HLA-A*02:01 matters for tebentafusp.
Main reasons for not taking part
- Brain metastases with symptoms that have not been treated
- Active uveitis that needs treatment
- Any primary immunodeficiency, such as SCID or AIDS
- Another primary cancer within the past 3 years
- Organ transplant, or cell therapy with conditioning chemotherapy, within the past 20 years
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participant must be ≥ 18 years of age at the time of signing the informed consent
- Participant has unresectable or metastatic melanoma
- Participant has melanoma not of uveal/ocular origin and experienced documented radiographic disease progression during systemic therapy with a PD-1/PD-L1 blocking antibody or within 12 weeks after the last dose of the PD-1/PD-L1 blocking antibody. If the tumor is BRAF V600 mutation positive, the participant also received or refused a BRAF inhibitor with or without a MEK inhibitor; OR Phase 1, Part 1 only: For participants with uveal melanoma, tebentafusp must have been received if available as standard of care (human leukocyte antigen [HLA]-A*02:01 positive participant and approved by local authorities for uveal melanoma) or refused
- Participant has an ECOG performance status of 0 or 1 and, in the investigator's opinion, an estimated life expectancy of > 6 months
- Phase 1, Part 2 only: Following tumor resection for lifileucel generation, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1
- Participant has recovered from all prior anticancer treatment-related AEs
Who cannot take part
- Participant had another primary malignancy within the previous 3 years
- Participants who require systemic steroid therapy 10 mg/day prednisone or another steroid equivalent dose
- Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years
- Participant is at an increased risk for systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems
- Participant has any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease [SCID] or AIDS)
- Participant has a history of hypersensitivity to any component of the study intervention
- Participant has symptomatic untreated brain metastases
- Participant has active uveitis that requires active treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
Also in 1 other country, 2 sites
- UNC Hospitals, The University of North Carolina at Chapel HillChapel Hill, United StatesContact: Iovance BiotherapeuticsTaking people
- SCRI Oncology Partners- DenverDenver, United StatesContact: Iovance BiotherapeuticsTaking people
- Sarah Cannon Research InstituteNashville, United StatesContact: Iovance BiotherapeuticsTaking people
About the trial
What the trial wants to find out
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
The group in the trial
- Assigned InterventionsTreatment being tested
Dose escalation participants with unresectable or metastatic melanoma
Treatment: IOV-3001
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel
- Plain-language title
- Tests IOV-3001 with lifileucel in adults with advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06940739, who can take part
- Record updated
- 15 June 2026